AI and data science aim to predict IBD treatment shifts

NCT ID NCT05733702

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 2 times

Summary

This study is collecting health data, voice recordings, and biological samples from 100 IBD patients in Luxembourg (part of a larger 800-person study across Europe). Researchers hope to find patterns that can predict when a patient's treatment needs to change. The goal is to use artificial intelligence and data science to improve personalized care for Crohn's disease and ulcerative colitis.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could help doctors predict when IBD patients need a treatment change, leading to more personalized and timely care.

What could go wrong

This is an observational study, not testing a new treatment. It may not find clear markers, and results may not apply to all patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CROHN DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Crohn disease inflammatory bowel disease ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Centre Hospitalier de Luxembourg (CHL)

    RECRUITING

    Luxembourg, L-1210, Luxembourg

    Contact Phone: •••-•••-•••• Email: •••••@•••••